Labcorp Holdings (LH) Draws Fresh Analyst Optimism, Is The Stock Still Cheap?
Labcorp Holdings (LH) is back in focus after increased analyst confidence, with upward earnings estimate revisions, expectations for higher revenue and earnings in the upcoming quarter, and fresh attention on its recent product launch.
See our latest analysis for Labcorp Holdings.
That growing confidence has shown up in the Labcorp Holdings share price, with a 9.3% 1 month share price return, a 12.66% 3 month share price return and a 17.93% year to date share price return. The 3 year total shareholder return of 43.35% points to momentum building over a longer horizon.
If you are looking for more ideas in healthcare, this is a good moment to scan companies using AI in medicine and diagnostics with the 40 healthcare AI stocks
Labcorp Holdings now trades close to analyst targets yet still screens at a sizeable discount to estimated fair value. Is the recent rally a catch up to fundamentals, or a sign that the market’s caution lingers for good reason?
Most Popular Narrative: 4.3% Undervalued
The most followed valuation narrative currently places Labcorp Holdings’ fair value at about $310 per share, slightly above the last close of $296.77. This frames the recent share price strength in a different light.
The analysts have a consensus price target of $310.12 for Labcorp Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $340.0, and the most bearish reporting a price target of just $270.0.
The narrative focuses on steady revenue expansion, thicker margins and a future earnings multiple that is projected to be below the wider Healthcare sector. This raises the question of which specific growth and profitability assumptions have to align for that fair value estimate to hold, and how much of today’s $14.1b revenue base would need to convert into higher earnings for the thesis to remain intact.
Result: Fair Value of $310 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Labcorp Holdings still faces pressure from potential PAMA related reimbursement cuts and ongoing competitive bidding, which could squeeze pricing and margins if conditions turn less favorable.
Find out about the key risks to this Labcorp Holdings narrative.
Next Steps
If this combination of opportunity and concern around Labcorp Holdings seems finely balanced, review the evidence now and weigh both sides for yourself using the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Labcorp Holdings?
Do not stop with Labcorp Holdings. Broaden your watchlist now with focused stock ideas filtered by quality, income potential and balance sheet strength using the Simply Wall St Screener.
- Target potential mispricings by reviewing companies that screen as quality businesses trading below estimated value through the 49 high quality undervalued stocks.
- Strengthen your income focus by scanning for companies offering higher yields in the 9 dividend fortresses.
- Prioritise resilience by filtering for companies with healthy financial footing through the solid balance sheet and fundamentals stocks screener (49 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com